NITD-349

CAS No. 1473450-62-2

NITD-349( NITD349 )

Catalog No. M12026 CAS No. 1473450-62-2

NITD-349 is a novel, orally bioavailable mycobacterial membrane protein Large 3 (MmpL3) inhibitor with MIC of 23 nM against M tuberculosis H37Rv.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 41 Get Quote
5MG 65 Get Quote
10MG 110 Get Quote
25MG 200 Get Quote
50MG 335 Get Quote
100MG 500 Get Quote
500MG 1098 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NITD-349
  • Note
    Research use only, not for human use.
  • Brief Description
    NITD-349 is a novel, orally bioavailable mycobacterial membrane protein Large 3 (MmpL3) inhibitor with MIC of 23 nM against M tuberculosis H37Rv.
  • Description
    NITD-349 is a novel, orally bioavailable mycobacterial membrane protein Large 3 (MmpL3) inhibitor with MIC of 23 nM against M tuberculosis H37Rv; shows potent activity against both drug-sensitive and multidrug-resistant clinical isolates of Mtb; demonstrates effectivity in treating both acute and chronic Mtb infections in mouse efficacy models.
  • In Vitro
    NITD-349 shows bactericidal activity against in vitro replicating Mycobacterium tuberculosis (Mtb) and also are active against intramacrophage Mtb. Kill kinetic analysis of these compounds showed both concentration- and time-dependent killing of Mtb cells with 3- to 4-log colony-forming unit (CFU) reductionwithin 3 days of treatment. The cidal activity profile of NITD-304 is similar to that of isoniazid for which rapid killing is noticed at concentrations greater than 0.2 μM. The MIC activity of NITD349 against various MDR Mtb strains ranges from 0.04 to 0.08 μM. NITD-349 shows high permeability and moderate in vitro metabolic clearance in mouse and human hepatic microsomes.
  • In Vivo
    In the acute murine efficacy modelNITD-349 shows favorable oral pharmacokinetic (PK) properties in rodents and dogs and are efficacious in mouse models of both acute and chronic Mycobacterium tuberculosis infection. In the acute murine efficacy model, treatment of mice with NITD-349 at doses of 12.5 and 50 mg/kg resulted in 0.9- and 3.4-log CFU reduction in lung tissue. In an established infection mouse model, after 2 weeks of treatment, the efficacy of NITD-349 is comparable to the first-line TB drug rifampicin and is better than ethambutol. Four weeks of treatment at 100 mg/kg with NITD-349 results in 2.38-log CFU reductions.
  • Synonyms
    NITD349
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    1473450-62-2
  • Formula Weight
    306.36
  • Molecular Formula
    C17H20F2N2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 310 mg/mL 1011.91 mM
  • SMILES
    CC1(CCC(CC1)NC(=O)C2=CC3=C(N2)C=C(C=C3F)F)C
  • Chemical Name
    N-(4,4-dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rao SP, et al. Sci Transl Med. 2013 Dec 4;5(214):214ra168.
molnova catalog
related products
  • Methenamine Hippurat...

    Methenamine Hippurate is a component of Hiprex with antibacterial activity.

  • Maleic acid

    Maleic Acid is a Glutamate Decarboxylase (GAD) inhibitor of E. coli and L. monocytogenes.

  • Terminolic acid

    Terminolic acid is a pentacyclic triterpenoid glucoside isolated from Combretum racemosum,?can inhibit the pro-inflammatory cytokines by binding to receptor active site of IL-1β and IL-6, and enhance anti-inflammatory cytokines by binding to IL-4 receptor binding sites.